Literature DB >> 16554259

Therapeutic interventions for tone abnormalities in cerebral palsy.

Ann H Tilton1.   

Abstract

Cerebral palsy (CP) is a common cause of movement disorders in children. The upper motor neuron syndrome of CP leads to several types of muscle overactivity, including spasticity. Reduction of muscle overactivity may be an important treatment goal, to improve comfort, care, and active function and to prevent future musculoskeletal complications. After a comprehensive team evaluation, a treatment plan is generated. Treatments may include physical and occupational therapy, oral medications, botulinum toxin and/or phenol injections, intrathecal baclofen, selective dorsal rhizotomy, and orthopedic surgery. Successful and early prevention of contracture may reduce the need for later corrective surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554259      PMCID: PMC3593441          DOI: 10.1016/j.nurx.2006.01.008

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  60 in total

1.  Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.

Authors:  R Baker; M Jasinski; I Maciag-Tymecka; J Michalowska-Mrozek; M Bonikowski; L Carr; J MacLean; J P Lin; B Lynch; T Theologis; J Wendorff; P Eunson; A Cosgrove
Journal:  Dev Med Child Neurol       Date:  2002-10       Impact factor: 5.449

Review 2.  Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial.

Authors:  J F McLaughlin; K F Bjornson; S J Astley; C Graubert; R M Hays; T S Roberts; R Price; N Temkin
Journal:  Dev Med Child Neurol       Date:  1998-04       Impact factor: 5.449

3.  Functional assessment of children with cerebral palsy following limited (L4-S1) selective posterior rhizotomy--a preliminary report.

Authors:  M Galarza; E G Fowler; L Chipps; T M Padden; J A Lazareff
Journal:  Acta Neurochir (Wien)       Date:  2001-09       Impact factor: 2.216

4.  [The use of sirdalud in cerebral palsy in children].

Authors:  I L Brin; A L Kurenkov; V Ia Gotlib
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  1999

5.  Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE).

Authors: 
Journal:  Dev Med Child Neurol       Date:  2000-12       Impact factor: 5.449

6.  Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study.

Authors:  P Van Schaeybroeck; B Nuttin; L Lagae; E Schrijvers; C Borghgraef; P Feys
Journal:  Neurosurgery       Date:  2000-03       Impact factor: 4.654

Review 7.  Outcomes after selective dorsal rhizotomy for spastic cerebral palsy.

Authors:  P Steinbok
Journal:  Childs Nerv Syst       Date:  2001-01       Impact factor: 1.475

8.  An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy.

Authors:  D Fehlings; M Rang; J Glazier; C Steele
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

9.  Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial.

Authors:  R Gilmartin; D Bruce; B B Storrs; R Abbott; L Krach; J Ward; K Bloom; W H Brooks; D L Johnson; J R Madsen; J F McLaughlin; J Nadell
Journal:  J Child Neurol       Date:  2000-02       Impact factor: 1.987

10.  Threshold electrical stimulation (TES) in ambulant children with CP: a randomized double-blind placebo-controlled clinical trial.

Authors:  Christine í Dali; Flemming Juul Hansen; Søren Anker Pedersen; Liselotte Skov; Jørgen Hilden; Inge Bjørnskov; Charlotte Strandberg; Jette Christensen; Ulla Haugsted; Grethe Herbst; Ulla Lyskjaer
Journal:  Dev Med Child Neurol       Date:  2002-06       Impact factor: 5.449

View more
  9 in total

Review 1.  New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy.

Authors:  Diane L Damiano; Katharine E Alter; Henry Chambers
Journal:  Phys Med Rehabil Clin N Am       Date:  2009-08       Impact factor: 1.784

2.  Pediatric neurotherapy.

Authors:  Leon S Dure; Faye Silverstein
Journal:  NeuroRx       Date:  2012-09-05

3.  Hamstring contractures in children with spastic cerebral palsy result from a stiffer extracellular matrix and increased in vivo sarcomere length.

Authors:  Lucas R Smith; Ki S Lee; Samuel R Ward; Henry G Chambers; Richard L Lieber
Journal:  J Physiol       Date:  2011-03-21       Impact factor: 5.182

Review 4.  Cerebral palsy gait, clinical importance.

Authors:  Raluca Dana Tugui; Dinu Antonescu
Journal:  Maedica (Buchar)       Date:  2013-09

5.  A soft-electronic sensor network tracks neuromotor development in infants.

Authors:  Yasser Khan; Zhenan Bao
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-16       Impact factor: 11.205

6.  Proteasome inhibition preserves longitudinal growth of denervated muscle and prevents neonatal neuromuscular contractures.

Authors:  Sia Nikolaou; Alyssa Aw Cramer; Liangjun Hu; Qingnian Goh; Douglas P Millay; Roger Cornwall
Journal:  JCI Insight       Date:  2019-12-05

7.  Outcomes of importance to children and young adults with cerebral palsy, their parents and health professionals following lower limb orthopaedic surgery: A qualitative study to inform a Core Outcome Set.

Authors:  Hajar Almoajil; Francine Toye; Helen Dawes; Jo Pierce; Andrew Meaney; Aziz Baklouti; Lara Poverini; Sally Hopewell; Tim Theologis
Journal:  Health Expect       Date:  2022-01-27       Impact factor: 3.318

8.  Brachial plexus birth injury and cerebral palsy lead to a common contracture phenotype characterized by reduced functional muscle length and strength.

Authors:  Sia Nikolaou; Micah C Garcia; Jason T Long; Allison J Allgier; Qingnian Goh; Roger Cornwall
Journal:  Front Rehabil Sci       Date:  2022-08-16

9.  Transcriptional abnormalities of hamstring muscle contractures in children with cerebral palsy.

Authors:  Lucas R Smith; Henry G Chambers; Shankar Subramaniam; Richard L Lieber
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.